CADTH Canadian drug expert committee recommendation: Erenumab (Aimovig -- Novartis pharmaceuticals Canada Inc.) indication: prevention of migraine
Erenumab has a Health Canada indication for the prevention of migraines in patients who have at least four migraine days monthly.It is a monoclonal antibody that binds to and inhibits calcitonin gene-related peptide and is administered by subcutaneous injectionat a dosage of either 70 mg or 140 mg o...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, July 2020
|
| Edition: | Version: 1.0 |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Erenumab has a Health Canada indication for the prevention of migraines in patients who have at least four migraine days monthly.It is a monoclonal antibody that binds to and inhibits calcitonin gene-related peptide and is administered by subcutaneous injectionat a dosage of either 70 mg or 140 mg once monthly. Erenumab is available as an autoinjector in 70 mg and 140 mg strengths |
|---|---|
| Physical Description: | 1 PDF file (10 pages) |